ASUS Republic of Gamers (ROG) has introduced the new ROG Hone Control Ace L Vitality Edition mouse pad at COMPUTEX 2026 in Taipei. Developed in partnership with Team Vitality, one of the world’s ...

Arcus Biosciences (RCUS) traded lower in the premarket on Monday after the oncology-focused biotech announced the discontinuation of a late-stage trial designed to evaluate its anti-TIGIT therapy ...

Arcus Biosciences is discontinuing a phase 3 lung cancer trial it was conducting with Gilead Sciences. Arcus, an oncology company, said Monday it was ending the trial due to futility, meaning it doesn ...

Add Outdoor Life (opens in a new tab) More information Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results. A ...

Add Yahoo as a preferred source to see more of our stories on Google. The short video clip shows the Burmese python regurgitating the bird whole in a matter of seconds. A professional python hunter in ...

Arcus Biosciences posted strong FY25 results, beating EPS and revenue estimates despite no commercial products and heavy R&D investment. RCUS’s valuation premium is driven by Casdatifan, a ...

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules for patients with cancer and ...

Arcus Infrastructure Partners will acquire Wifinity, a UK-based internet managed services provider, from LDC and Literacy Capital. Literacy will generate a total expected return of 5.2x MoM, in line ...

Rochdale, England-based WCCTV was formed in 2001 Arcus’ investment will be made via Arcus European Infrastructure Fund 4 SCSp LDC initially invested in WCCTV in 2021 LDC will exit its investment in ...

Dec 12 (Reuters) - Arcus Biosciences (RCUS.N), opens new tab said on Friday it would stop a late-stage study testing its experimental cancer drug combination in patients with advanced stomach and ...

A key late-stage trial of Arcus Biosciences and Gilead Sciences' anti-TIGIT antibody domvanalimab has flopped, leading Arcus to refocus its R&D priorities and abandon several studies of the drug. The ...